Nippon Kayaku Co., Ltd. and AnHeart Therapeutics Inc. announced that the two companies have entered into a licensing agreement. Under the Agreement, Nippon Kayaku obtains the exclusive rights to market and distribute Taletrectinib (Development code: AB-106/DS-6051b; hereinafter "the Product"), a novel, next-generation, brain-penetrant, selective ROS1 inhibitor currently under development by AnHeart, for the territory of Japan. The company shall continue to conduct global Phase II clinical trials for the development of the Product, and Nippon Kayaku shall be responsible for the regulatory application for approval, packaging, labeling, distribution, sales, promotion, etc.

of the Product in Japan. Nippon Kayaku is to make an upfront payment of $40 million to AnHeart upon the signing of the Agreement, and make further milestone payments in the event of future regulatory approval, domestic sales exceeding certain amounts, and royalties based on domestic net sales.